Cytochrome P450 enzymes: Novel options for cancer therapeutics

Molecular Cancer Therapeutics

Volumn 3, Issue 3, 2004, Pages 363-371

  McFadyen, Morag C E ^a   Melvin, William T ^a   Murray, Graeme I ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1B1; CYTOTOXIC AGENT; DACARBAZINE; DNA VACCINE; DOCETAXEL; DOXORUBICIN; ELLIPTICINE; ETOPOSIDE; GENISTEIN; IFOSFAMIDE; IRINOTECAN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PROCARBAZINE; RESVERATROL; RETINOIC ACID; RETINOID; TAMOXIFEN; TEGAFUR; TENIPOSIDE; THIOTEPA; TOPOTECAN; TRICHOSTATIN A; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER CHEMOTHERAPY; DRUG TARGETING; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; POLYMORPHISM, GENETIC; RNA, MESSENGER;

EID: 4444223732     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (87)

1. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet, 2002;360:1155-62.
2. Conley A, Hinshelwood M. Mammalian aromatases. Reproduction, 2001;121:685-95.
3. Capdevilla JH, Flack JR, Eastabrook RW. Cytochrome P450 and the arachidonate cascade. FASEB J, 1992;6:731-6.
4. Gut I, Danielova V, Holubova J, Soucek P, Kluckova H. Cytotoxicity of cyclophosphamide, paclitaxel, and docetaxel for tumor cell lines in vitro: effects of concentration, time and cytochrome P450-catalyzed metabolism. Arch Toxicol, 2000;74:437-46.
5. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamicle. Biochem Pharmacol, 2000;59:61-72.
6. Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev, 1994;26:165-83.
7. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anti-cancer agents: implications for drug interactions. Br J Clin Pharmacol, 1995;40:523-30.
8. Mace K, Bowman ED, Vautravers P, Shields PG, Harris CC, Pfeifer AM. Characterization of xenobiotic-metabolizing enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur J Cancer, 1998;34: 914-20.
9. Murray GI, McFadyen MCE, Mitchell RT, Cheung YL, Kerr AC, Melvin, WT. Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer, 1999;79:1836-42.
10. Hashizume T, Imaoka S, Mise M, et al. Involvement of CYP2J2 and CYP2F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther, 2002;300:298-304.
11. Murray GI, Taylor MC, McFadyen MCE, et al. Tumor specific expression of cytochrome P450 CYP1B1. Cancer Res, 1997;57:3026-31.
12. Murray GI. The role of cytochrome P450 in tumor development and progression and its potential in therapy. J Pathol, 2000;192:419-26.
13. McFadyen MCE, Cruickshank ME, Miller ID, et al. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer, 2001;85:242-6.
14. Bareis P, Bises G, Bischof MG, Cross HS, Peterlik M. 25-Hydroxyvitamin D metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun, 2001;285:1012-7.
15. Murray GI, Foster CO, Barnes TS, et al. Expression of cytochrome P450 CYP1A1 in breast cancer. Br J Cancer, 1991;63:1021-3.
16. Gibson P, Gill JH, Khan PA, et al. Cytochrome P4501B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol Cancer Ther, 2003;2:527-34.
17. Godoy W, Albano RM, Moraes EG, et al. CYP2A6/2A7 and CYP2E1 expression in human esophageal mucosa: regional and inter-individual variation in expression and relevance to nitrosamine metabolism. Carcinogenesis, 2002;23:611-6.
18. Murray GI, Shaw D, Weaver RJ, et al. Cytochrome P450 expression in esophageal cancer. Gut, 1994;35:599-603.
19. Dhaini HR, Thomas DG, Giordano TJ, et al. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol, 2003;21:2481-5.
20. Murray GI, McKay JA, Weaver RJ, Ewen SW, Melvin WT, Burke MD. Cytochrome P450 expression is a common molecular event in soft tissue sarcomas. J Pathol, 1993;171:49-52.
21. Murray GI, Melvin WT, Greenlee WF, Melvin WT. The regulation, function and tissue specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol, 2001;41:297-316.
22. McFadyen MCE, Breeman S, Payne S, et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem, 1999;47: 1457-64.
23. McKay JA, Melvin WT, Ah-See AK, et al. Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Lett, 1995;374:270-2.
24. Gordan JD, Vonderheide RH. Universal tumor antigens as targets for immunotherapy. Cytotherapy, 2002;4:317-27.
25. Tangpricha V, Flanagan JN, Whitlatch LW, et al. 25-Hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue. Lancet, 2001;357: 1673-4.
26. Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy, 2003;23:165-72.
27. Dawling S, Roodi N, Parl FF. Methoxyestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B1. Cancer Res, 2003;63:3127-32.
28. Jennewein S, Rithner CD, Williams RM, Croteau RB. Taxol biosynthesis: taxane: 13α-hydroxylase is a cytochrome P450-dependent mono-oxygenase. Proc Natl Acad Sci USA, 2001;98:13595-600.
29. Wheeler AL, Long RM, Ketchum REB, Rithner CD, Williams RM, Croteau R. Taxol biosynthesis: differential transformations of taxadien-5α-ol and its acetate ester by cytochrome P450 hydroxylases from Taxus suspension cells. Arch Biochem Biophys, 2001; 390:265-78.
30. Da Rocha AB, Lopes RM, Schwartsmann G. Natural products in anticancer therapy. Curr Opin Pharmacol, 2001;1:364-9.
31. Irmler S, Schroder G, St Pierre B, et al. Indole alkaloid biosynthesis in Catharanthus roseus: new enzyme activities and identification of cytochrome P450 CYP72A1 as secloganin synthase. Plant J, 2000;24: 797-804.
32. Collu G, Unver N, Peltenburg-Loonman AMG, van der Heijden R, Verpoorte R, Memelink J. Geraniol 10-hydroxylase, a cytochrome P450 enzyme involved in terpenoid indole alkaloid biosynthesis. FEES Lett, 2001;508:215-20.
33. Sovak M. Grape extract, resveratrol, and its analogs: a review. J Med Food, 2001;4:93-105.
34. Potter GA, Patterson LH, Wanogho E, et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by cytochrome P450 enzyme CYP1B1. Br J Cancer, 2002;86:774-8.
35. Gray Cancer Institute, Research Report 2001.
36. Cancer Research UK, Scientific Yearbook 2001-2002.
37. Trapani V, Patel V, Leong CO, et al. DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. Br J Cancer, 2003;88:599-605.
38. Leong CO, Gaskell M, Martin EA, et al. Antitumor 2-(4-amino-phenyl)benzothiazoles generate DNA adducts in sensitive tumor cells in vitro and in vivo. Br J Cancer, 2003;88:470-7.
39. Brockdorff BL, Skouv J, Reiter BE, Lykkesfeldt AE. Increased expression of cytochrome P4501A1 and 1B1 genes in anti-estrogen-resistant human breast cancer cell lines. Int J Cancer, 2000;88:902-6.
40. Patterson LH. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev, 2002;34:581-92.
41. Denny WA. The role of hypoxia-activated pro-drugs in cancer therapy. Lancet Oncol, 2000;1:25-9.
42. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab, 2002;3:561-97.
43. McKeown SR, Hejmadi MV, McIntyre IA, McAleer JJ, Patterson LH. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer, 1995;72: 76-81.
44. Hejmadi MV, McKeown SR, Friary OP, McIntyre IA, Patterson LH, Hirst DG. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumor cells. Br J Cancer, 1996;73:499-505.
45. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer, 2000;83:1589-93.
46. Ali MM, Symons MC, Taiwo FA, Patterson LH. Effects of AQ4N and its reduction product on radiation-mediated DNA strand breakage. Chem Biol Interact, 1999;123:1-10.
47. McCarthy HO, Yakkundi A, McErlane V, et al. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther, 2003;10:40-8.
48. Wei MX, Tamiya T, Chase M, et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther, 1994;5:969-78.
49. Löhr M, Hoffmeyer A, Kröger J-C, et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet, 2001; 357:1591-2.
50. Manome Y, Wen PY, Chen L, et al. Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther, 1996;3:513-20.
51. Chen L, Waxman DJ, Chen D, Kufe DW. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res, 1996;56:1331-40.
52. Hunt S. Technology evaluation: MetXia-P450, Oxford Biomedica. Curr Opin Mol Ther, 2001;3:595-8.
53. Kan O, Kingsman S, Naylor S. Cytochrome P450-based cancer gene therapy: current status. Exp Opin Biol Ther, 2002;2:857-68.
54. Griffiths L, Binley K, Iqball S, et al. The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Ther, 2000;3: 255-62.
55. Schwartz PS, Chong-Sheng C, Waxman DJ. Enhanced bystander cytotoxicity of P450 gene-directed enzyme pro-drug therapy by expression of the antiapoptotic factor p35. Cancer Res, 2002;62:6928-37.
56. Yao D, Ding S, Burchell B, Wolf CR, Friedberg T. Detoxication of Vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther, 2000;294:387-95.
57. Crommentuyn KML, Schellens JHM, van der Berg JD, Beijnen JH. In vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide. Cancer Treat Rev, 1998; 24: 345-66.
58. Kostrubsky VE, Lewis LD, Strom SC, et al. Induction of cytochrome P4503A by Taxol in primary cultures of human hepatocytes. Arch Biochem Biophys, 1998;355:131-6.
59. Fujitaka K, Oguri T, Isobe T, Fujiwara Y, Kohno N. Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. Cancer Chemother Pharmacol, 2001;48:42-6.
60. Nallani SC, Genter MB, Desai PB. Increased activity of CYP3A enzymes in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel. Cancer Chemother Pharmacol, 2001;48:115-22.
61. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med, 2001;7: 584-90.
62. Albertson DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet, 2000;25:144-6.
63. Cross HS, Kallay E, Farhan H, Weiland T, Manhardt T. Regulation of extrarenal vitamin D metabolism as a tool for colon and prostate cancer prevention. Recent Results Cancer Res, 2003;164:413-25.
64. Farhan H, Cross HS. Transcriptional inhibition of CYP24 by genistein. Ann NY Acad Sci, 2002;973:459-62.
65. Njar VC. Cytochrome P450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. Mini Rev Med Chem, 2002;2:261-9.
66. Ozpolat B, Mehta K, Tari AM. All-trans-retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. Am J Hematol, 2002;70:39-47.
67. Mira-Y-Lopez R, Zheng WL, Kuppumbatti YS, Rexer B, Jing Y, Ong DE. Retinol conversion to retinoic acid is impaired in breast cancer cell lines relative to normal cells. J Cell Physiol, 2000;185:302-9.
68. Peehl DM, Wong ST, Stamey TA. Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate, 1993;23: 69-78.
69. Pasquali D, Rossi V, Prezioso D, et al. Changes in tissue transglutaminase activity and expression during retinoic acid-induced growth arrest and apoptosis in primary cultures of human epithelial prostate cells. J Clin Endocrinol Metab, 1999;84:1463-9.
70. Arora V, Cate ML, Ghosh C, Iversen PL. Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab Dispos, 2002; 30:757-62.
71. Nallani SC, Goodwin B, Maglich JM, Buckley DJ, Buckley AR, Desai PB. Induction of cytochrome P450 3A by paclitaxel in mice: pivotal role of the nuclear xenobiotic receptor, pregnane X receptor. Drug Metab Dispos, 2003;31:681-4.
72. Kajita J, Kuwabara T, Kobayashi H, Kobayashi S. CYP3A4 is mainly responsible for the metabolism of a new Vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos, 2000;28:1121-7.
73. Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer, 1998;34:1493-9.
74. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res, 1996;56:1296-302.
75. Sonnichsen DS, Relling MV. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet, 1994;27:256-69.
76. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol, 2001;62: 207-12.
77. Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther, 2001;296: 537-41.
78. Bournique B, Lemarie A. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab Dispos, 2002;30:1149-52.
79. Maecker B, Sherr DH, Vonderheide RH, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood, 2003;102:3287-94.
80. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci, 1999;20:342-9.
81. Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther, 2001;299:825-31.
82. Stiborova M, Bieler CA, Wiessler M, Frei E. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 2001;62:1675-84.
83. Kawashiro T, Yamashita K, Zhao XJ, et al. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther, 1998; 286:1294-300.
84. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol, 1994;45:352-8.
85. Vassal G, Pondarre C, Boland I, et al. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie, 1998;80:271-80.
86. Patterson LH, Murray GI. Tumor cytochrome P450 and drug activation. Curr Pharm Des, 2002;8:1335-47.
87. Jacobson PA, Green K, Birnbaum A, Remmel RP. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol, 2002; 49:461-7.